QuitPak is Cary's combination product containing bupropion and mecamylamine and is intended as an alternative therapy in smoking cessation.
The purpose of the study is to determine the suitability of IntelGenx' newly developed extended-release formulation for the once-daily administration of bupropion and mecamylamine.
In the course of the study, rate and extent of the absorption of the two actives will be monitored. The data obtained from this trial will be used to determine if the formulation is suitable for once-daily co-administration of the two actives.
“The data gathered during this trial will provide important information regarding the suitability of our new extended-release formulation for further phase I and IIb studies that will be conducted later this year,” said Dr Horst Zerbe, CEO of IntelGenx.